Trial Profile
A Phase I, Single Blind, Placebo-controlled, Randomized Study to Assess the Safety of DS-1040b in Subjects With Thrombectomy Treated Acute Ischemic Stroke
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs DS 1040 (Primary)
- Indications Stroke
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Company
- 12 Jan 2022 Results investigating safety, pharmacokinetics, and pharmacodynamics of DS-1040 published in the Clinical Drug Investigation
- 07 Feb 2020 Status changed from active, no longer recruiting to completed.
- 29 Nov 2019 Status changed from recruiting to active, no longer recruiting.